Nathan Wong/LinkedIn
Feb 1, 2026, 11:24
Nathan Wong on Economic Benefits of Inclisiran for LDL-C Control
Nathan Wong, Professor and Director, Heart Disease Prevention Program, Division of Cardiology, UC Irvine, shared on LinkedIn:
”Our latest paper in JACC Journals projects approximately 20 million US adults with inadequately controlled LDL-C on statins could benefit from inclisiran treatment, preventing more than 1.6 million ASCVD events over 10 years.”
Read the full article here.
Article: Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
Authors: Nathan Wong, Hridhay Karthikeyan, Wenjun Fan, Batul Electricwala
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 27, 2026, 01:21Michelle Sámano Sánchez: Exploring Vitamin C as an Adjunct Therapy for Anemia in Hemodialysis
-
Jun 27, 2026, 01:08Ana Raquel Gotine: The First Pragmatic Clinical Trial on MNPs and Childhood Anemia in Mozambique
-
Jun 27, 2026, 00:56Sherif Badawy: Reflecting on My Time with ASH CRTI
-
Jun 27, 2026, 00:48Zain Khalpey: Why High quality CPR is Only Part of Successful Cardiac Arrest Management
-
Jun 26, 2026, 22:31Wendy Dusenbury: The New Issue of the Stroke Clinician is Now Live
-
Jun 26, 2026, 20:42Ed Watson: When It Happens to You, Stroke Becomes Personal, Immediate, and Life-Changing
-
Jun 26, 2026, 19:45Nathan Connell: Transforming Surgical Care with Tranexamic Acid
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century